Kymera Therapeutics, Inc. Expected to Earn Q1 2024 Earnings of ($0.79) Per Share (NASDAQ:KYMR)

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) – Equities research analysts at B. Riley issued their Q1 2024 EPS estimates for Kymera Therapeutics in a research note issued to investors on Friday, February 23rd. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($0.79) for the quarter. The consensus […]

Related Keywords

Jeffreyw Albers ,Stifel Nicolaus ,Piper Sandler ,Jared Gollob ,Blackrock Inc ,Kymera Therapeutics Company Profile ,Morgan Stanley ,Kymera Therapeutics Inc ,Nasdaq ,Metlife Investment Management ,Dimensional Fund Advisors ,Securities Exchange Commission ,Wells Fargo Company ,York Mellon Corp ,Kymera Therapeutics ,Free Report ,Kymera Therapeutic ,Get Free Report ,Wells Fargo ,Director Jeffrey ,Exchange Commission ,New York Mellon Corp ,Life Investment Management ,Fund Advisors ,Kymera Therapeutics Daily ,Nasdaq Kymr ,Kymr ,Medical ,Earnings Estimates ,B Riley ,